2.3.1.122 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24455775&form=6&db=m Administration of mycobacterial Ag85A and IL-17A fusion protein attenuates airway inflammation in a murine model of asthma. causal interaction,ongoing research,therapeutic application,unassigned 2,4,1,0 2.3.1.122 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29302700&form=6&db=m Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. ongoing research,therapeutic application,unassigned 4,2,0 2.3.1.122 Buruli Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11500410&form=6&db=m Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. therapeutic application,unassigned 2,0 2.3.1.122 Buruli Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26393347&form=6&db=m Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. ongoing research,therapeutic application,unassigned 2,3,0 2.3.1.122 Buruli Ulcer http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30090691&form=6&db=m IFN-? and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,2,0 2.3.1.122 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238268&form=6&db=m Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.122 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30542467&form=6&db=m Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity. unassigned - 2.3.1.122 Coinfection http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23369570&form=6&db=m A novel DNA vaccine expressing the Ag85A-HA2 fusion protein provides protection against influenza A virus and Staphylococcus aureus. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Extensively Drug-Resistant Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33333421&form=6&db=m Identification of potent Antigen 85C inhibitors of Mycobacterium tuberculosis via in-house lichen library and binding free energy studies Part-II. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.122 Fowlpox http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15196215&form=6&db=m Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-GuĆ©rin. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Fowlpox http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15687025&form=6&db=m Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. unassigned - 2.3.1.122 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14623163&form=6&db=m Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Granuloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16815096&form=6&db=m Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18621704&form=6&db=m In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Hepatitis B http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29386070&form=6&db=m Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9529077&form=6&db=m Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. ongoing research,therapeutic application,unassigned 2,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9596772&form=6&db=m Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11009076&form=6&db=m CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11895982&form=6&db=m Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. ongoing research,therapeutic application,unassigned 2,3,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16169132&form=6&db=m Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387702&form=6&db=m Novel Bacterial Delivery System with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85A for Mucosal Immunization: Establishment of Proof of Principle in TB Mouse Model. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16827893&form=6&db=m Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. ongoing research,therapeutic application,unassigned 2,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18280621&form=6&db=m Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. therapeutic application,unassigned 2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19264552&form=6&db=m Post-exposure vaccination against Mycobacterium tuberculosis. unassigned - 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21093603&form=6&db=m The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21819455&form=6&db=m The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22406425&form=6&db=m Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. diagnostic usage,therapeutic application,unassigned 2,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22570667&form=6&db=m Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B. diagnostic usage,unassigned 1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23133523&form=6&db=m Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23579789&form=6&db=m Immunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24137516&form=6&db=m Correction: Immunogenicity of a Fusion Protein Containing Immunodominant Epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in Mice and Active TB Infection. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24392169&form=6&db=m Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice. causal interaction,therapeutic application,unassigned 1,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25398087&form=6&db=m A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26858942&form=6&db=m Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection. therapeutic application,unassigned 2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27498622&form=6&db=m Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29940854&form=6&db=m Rapid loss of early antigen-presenting activity of lymph node dendritic cells against Ag85A protein following Mycobacterium bovis BCG infection. causal interaction,therapeutic application,unassigned 3,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30312318&form=6&db=m Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30687792&form=6&db=m Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30851131&form=6&db=m Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. causal interaction,ongoing research,unassigned 1,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30939065&form=6&db=m Transforming Growth Factor-? Suppresses Interleukin (IL)-2 and IL-1? Production in HIV-Tuberculosis Co-Infection. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31786669&form=6&db=m Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33072631&form=6&db=m IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.122 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23223215&form=6&db=m Molecular adjuvant Ag85A enhances protection against influenza A virus in mice following DNA vaccination. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.3.1.122 Influenza, Human http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23369570&form=6&db=m A novel DNA vaccine expressing the Ag85A-HA2 fusion protein provides protection against influenza A virus and Staphylococcus aureus. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Leprosy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520418&form=6&db=m T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. unassigned - 2.3.1.122 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31198944&form=6&db=m Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation. ongoing research,unassigned 3,0 2.3.1.122 Lymphadenitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212340&form=6&db=m Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. diagnostic usage,ongoing research,unassigned 4,4,0 2.3.1.122 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15547707&form=6&db=m Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.122 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15547707&form=6&db=m Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.122 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26238268&form=6&db=m Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.3.1.122 Paratuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16368974&form=6&db=m Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Paratuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22128161&form=6&db=m Novel mycobacteria antigen 85 complex binding motif on fibronectin. ongoing research,unassigned 3,0 2.3.1.122 Pleurisy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31103419&form=6&db=m Down regulation of RANTES in pleural site is associated with inhibition of antigen specific response in tuberculosis. ongoing research,unassigned 4,0 2.3.1.122 Sarcoidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17357846&form=6&db=m Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 2.3.1.122 Schistosomiasis mansoni http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30687792&form=6&db=m Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3053775&form=6&db=m Humoral immune response in human tuberculosis: immunoglobulins G, A, and M directed against the purified P32 protein antigen of Mycobacterium bovis bacillus Calmette-GuĆ©rin. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7520418&form=6&db=m T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7959881&form=6&db=m Antigen 85C on Mycobacterium bovis, BCG and M. tuberculosis promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9193782&form=6&db=m Induction of humoral and cellular immune responses by vaccination with M. tuberculosis antigen 85 DNA. diagnostic usage,therapeutic application,unassigned 1,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9353028&form=6&db=m Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9361426&form=6&db=m Heterologous expression of the Mycobacterium tuberculosis gene encoding antigen 85A in Corynebacterium glutamicum. ongoing research,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9529077&form=6&db=m Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. ongoing research,therapeutic application,unassigned 2,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9596772&form=6&db=m Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10200974&form=6&db=m Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10639445&form=6&db=m Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10655605&form=6&db=m Another brick in the wall. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10655617&form=6&db=m Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10692994&form=6&db=m Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10858194&form=6&db=m Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11009076&form=6&db=m CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A. diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11120838&form=6&db=m Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11254389&form=6&db=m An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11854254&form=6&db=m Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11895982&form=6&db=m Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. ongoing research,therapeutic application,unassigned 2,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11940150&form=6&db=m The M. tuberculosis antigen 85 complex and mycolyltransferase activity. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12065510&form=6&db=m Improved tuberculosis DNA vaccines by formulation in cationic lipids. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496199&form=6&db=m Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12496215&form=6&db=m Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12575176&form=6&db=m [Molecular cloning and expression of the immunodominant protein Ag85A from Mycobacterium tuberculosis H37Rv strain] diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12623271&form=6&db=m Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. diagnostic usage,ongoing research,unassigned 1,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12758196&form=6&db=m Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. causal interaction,therapeutic application,unassigned 2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12907951&form=6&db=m Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14623163&form=6&db=m Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15177473&form=6&db=m Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall. diagnostic usage,ongoing research,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15192106&form=6&db=m Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15309815&form=6&db=m Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15502839&form=6&db=m Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. diagnostic usage,ongoing research,unassigned 1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15528375&form=6&db=m Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. ongoing research,therapeutic application,unassigned 1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15557632&form=6&db=m A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. diagnostic usage,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15687020&form=6&db=m TB vaccines for the World. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15908384&form=6&db=m Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15908420&form=6&db=m Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. ongoing research,therapeutic application,unassigned 1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15944305&form=6&db=m Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15993451&form=6&db=m T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. diagnostic usage,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16150517&form=6&db=m Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16169132&form=6&db=m Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16343993&form=6&db=m Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16352377&form=6&db=m Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to an epitope on antigen 85A. ongoing research,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16387702&form=6&db=m Novel Bacterial Delivery System with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85A for Mucosal Immunization: Establishment of Proof of Principle in TB Mouse Model. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16405398&form=6&db=m Improved humoral immunity against tuberculosis ESAT-6 antigen by chimeric DNA prime and protein boost strategy. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16488518&form=6&db=m Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16504584&form=6&db=m Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16622212&form=6&db=m Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16622219&form=6&db=m The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. diagnostic usage,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16815096&form=6&db=m Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16827893&form=6&db=m Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. ongoing research,therapeutic application,unassigned 2,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16847108&form=6&db=m Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16849488&form=6&db=m Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. diagnostic usage,ongoing research,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16861689&form=6&db=m Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16870530&form=6&db=m Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. ongoing research,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17052817&form=6&db=m Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. ongoing research,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17079254&form=6&db=m Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17357846&form=6&db=m Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17526747&form=6&db=m Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. causal interaction,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17570535&form=6&db=m Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17597917&form=6&db=m Docking of phosphonate and trehalose analog inhibitors into M. tuberculosis mycolyltransferase Ag85C: Comparison of the two scoring fitness functions GoldScore and ChemScore, in the GOLD software. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17764918&form=6&db=m Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17765917&form=6&db=m Validation of peptide epitope microarray experiments and extraction of quality data. diagnostic usage,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18280621&form=6&db=m Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. therapeutic application,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18300037&form=6&db=m Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and Bacillus Galmette-GuĆ©rin. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18350112&form=6&db=m Improved Protective Efficacy of a Species-Specific DNA Vaccine Encoding Mycolyl-Transferase Ag85A from Mycobacterium ulcerans by Homologous Protein Boosting. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18391552&form=6&db=m A simple immunomonitoring procedure for mRNA-loaded dendritic cell therapy. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18450455&form=6&db=m Synthesis of methyl 5-S-alkyl-5-thio-D-arabinofuranosides and evaluation of their antimycobacterial activity. ongoing research,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18602439&form=6&db=m The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18621704&form=6&db=m In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18682270&form=6&db=m Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18698342&form=6&db=m Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18702747&form=6&db=m Diagnostic potential of Ag85C in comparison to various secretory antigens for childhood tuberculosis. diagnostic usage,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18992216&form=6&db=m A coupled assay measuring Mycobacterium tuberculosis antigen 85C enzymatic activity. diagnostic usage,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19052643&form=6&db=m Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung. diagnostic usage,therapeutic application,unassigned 1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19052863&form=6&db=m Antigen 85C-mediated acyl-transfer between synthetic acyl donors and fragments of the arabinan. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19064635&form=6&db=m Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19356615&form=6&db=m A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19367339&form=6&db=m MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19450898&form=6&db=m Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19487476&form=6&db=m Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. therapeutic application,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19628675&form=6&db=m Mycolyltransferase from Mycobacterium leprae excludes mycolate-containing glycolipid substrates. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19668859&form=6&db=m Design, synthesis and biological evaluation of sugar-derived esters, alpha-ketoesters and alpha-ketoamides as inhibitors for Mycobacterium tuberculosis antigen 85C. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19837843&form=6&db=m Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19857528&form=6&db=m The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: Development of a novel assay and quantification of glycolipid- status of the mycobacterial cell wall. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20017188&form=6&db=m Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20140824&form=6&db=m MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20558252&form=6&db=m Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20694950&form=6&db=m Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity. ongoing research,therapeutic application,unassigned 4,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20942964&form=6&db=m Chemokine gene expression in lung CD8 T cells correlates with protective immunity in mice immunized intra-nasally with Adenovirus-85A. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21073150&form=6&db=m Novel Small Molecule Inhibitors of MDR Mycobacterium tuberculosis by NMR Fragment Screening of Antigen 85C. therapeutic application,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21093603&form=6&db=m The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21212022&form=6&db=m Vaccine for tuberculosis: Up-regulation of IL-15 by Ag85A and not by ESAT-6. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21253450&form=6&db=m Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21352251&form=6&db=m Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21461375&form=6&db=m Immunogenicity and Protective Efficacy against Murine Tuberculosis of a Prime-Boost Regimen with BCG and a DNA Vaccine Expressing ESAT-6 and Ag85A Fusion Protein. therapeutic application,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21603645&form=6&db=m Dual neonate vaccine platform against HIV-1 and M. tuberculosis. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21628524&form=6&db=m CXCR6 Is a Marker for Protective Antigen-Specific Cells in the Lungs after Intranasal Immunization against Mycobacterium tuberculosis. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21819455&form=6&db=m The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation. causal interaction,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22072720&form=6&db=m Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22164290&form=6&db=m Discovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screen. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22200502&form=6&db=m Epitope based recombinant BCG vaccine elicits specific Th1 polarized immune responses in BALB/c mice. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22290959&form=6&db=m Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. therapeutic application,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22396020&form=6&db=m Prime-boost vaccination with rBCG/rAd35 enhances CD8+ cytolytic T cell responses in lesions from Mycobacterium tuberculosis-infected primates. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22406425&form=6&db=m Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. diagnostic usage,therapeutic application,unassigned 2,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22461526&form=6&db=m A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22470455&form=6&db=m Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22540309&form=6&db=m Enhanced Cellular Immune Response Elicited by a DNA Vaccine Fused with Ub Against Mycobacterium tuberculosis. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22570667&form=6&db=m Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B. diagnostic usage,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22702139&form=6&db=m [Production of mycobacterial antigenes merged with cellulose binding protein domain in order to produce subunit vaccines against tuberculosis]. ongoing research,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22761299&form=6&db=m Goats Primed with Mycobacterium bovis BCG and Boosted with a Recombinant Adenovirus Expressing Ag85A Show Enhanced Protection against Tuberculosis. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22789508&form=6&db=m Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23133523&form=6&db=m Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23157580&form=6&db=m Antigen 85A and mycobacterial DNA-binding protein 1 are targets of immunoglobulin G in individuals with past tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23190459&form=6&db=m Design, synthesis, and X-ray analysis of a glycoconjugate bound to Mycobacterium tuberculosis antigen 85C. diagnostic usage,ongoing research,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23223215&form=6&db=m Molecular adjuvant Ag85A enhances protection against influenza A virus in mice following DNA vaccination. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23238272&form=6&db=m Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23262169&form=6&db=m Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A. ongoing research,therapeutic application,unassigned 4,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23369570&form=6&db=m A novel DNA vaccine expressing the Ag85A-HA2 fusion protein provides protection against influenza A virus and Staphylococcus aureus. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23554685&form=6&db=m Identification of distant co-evolving residues in antigen 85C from Mycobacterium tuberculosis using statistical coupling analysis of the esterase family proteins. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23571106&form=6&db=m A whole blood assay as a simple, broad assessment of cytokines and chemokines to evaluate human immune responses to Mycobacterium tuberculosis antigens. diagnostic usage,ongoing research,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23579789&form=6&db=m Immunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23675482&form=6&db=m Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23707076&form=6&db=m Novel particulate vaccines utilizing polyester nanoparticles (bio-beads) for protection against Mycobacterium bovis infection-A review. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23844129&form=6&db=m Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23896422&form=6&db=m Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. ongoing research,therapeutic application,unassigned 2,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24137516&form=6&db=m Correction: Immunogenicity of a Fusion Protein Containing Immunodominant Epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in Mice and Active TB Infection. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24192709&form=6&db=m Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24222196&form=6&db=m Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24283772&form=6&db=m Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24681608&form=6&db=m Immunogenicity of a Recombinant Mycobacterium smegmatis Vaccine Expressing the Fusion Protein CMX in Cattle from Goiįs State, Brazil. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24828094&form=6&db=m Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24941747&form=6&db=m [Construction and expression of a eukaryotic vector co-expressing immunodominant antigens of CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis]. diagnostic usage,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24980867&form=6&db=m A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25024382&form=6&db=m Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25071781&form=6&db=m The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25466778&form=6&db=m Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25612873&form=6&db=m Construction of two Listeria ivanovii attenuated strains expressing Mycobacterium tuberculosis antigens for TB vaccine purposes. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25726088&form=6&db=m Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25962477&form=6&db=m Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice. ongoing research,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26076321&form=6&db=m Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. ongoing research,therapeutic application,unassigned 4,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26111521&form=6&db=m Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26478198&form=6&db=m Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26552486&form=6&db=m Mycobacterium tuberculosis secretory proteins downregulate T cell activation by interfering with proximal and downstream T cell signalling events. diagnostic usage,ongoing research,unassigned 3,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26632438&form=6&db=m An In Silico Approach for Identification of Potential Anti-Mycobacterial Targets of Vasicine and Related Chemical Compounds. diagnostic usage,therapeutic application,unassigned 3,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26858942&form=6&db=m Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection. therapeutic application,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27154390&form=6&db=m Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27626449&form=6&db=m Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27703038&form=6&db=m Induction of an Immune-Protective T-Cell Repertoire With Diverse Genetic Coverage by a Novel Viral-Vectored Tuberculosis Vaccine in Humans. therapeutic application,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27999240&form=6&db=m Immunogenicity of a DNA Vaccine Encoding Ag85a-Tb10.4 Antigens from Mycobacterium Tuberculosis. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28273423&form=6&db=m Thermal and Photoinduced Copper-Promoted C-Se Bond Formation: Synthesis of 2-Alkyl-1,2-benzisoselenazol-3(2H)-ones and Evaluation against Mycobacterium tuberculosis. diagnostic usage,ongoing research,unassigned 1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28285521&form=6&db=m Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives. diagnostic usage,ongoing research,unassigned 3,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28392505&form=6&db=m Early Diagnosis of Tuberculosis-Associated IgA Nephropathy with ESAT-6. diagnostic usage,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28446902&form=6&db=m Modulation of Macrophage Responses by CMX, a Fusion Protein Composed of Ag85c, MPT51, and HspX from Mycobacterium tuberculosis. ongoing research,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28470626&form=6&db=m Novel adjuvant for immunization against tuberculosis: DNA vaccine expressing Mycobacterium tuberculosis antigen 85A and interleukin-15 fusion product elicits strong immune responses in mice. ongoing research,therapeutic application,unassigned 1,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28633546&form=6&db=m Identification of specific antibodies against the Ag85C-MPT51-HspX fusion protein (CMX) for serological screening of tuberculosis in endemic area. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28633702&form=6&db=m Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28713817&form=6&db=m Generation of Monoclonal Antibodies against Ag85A Antigen of Mycobacterium tuberculosis and Application in a Competitive ELISA for Serodiagnosis of Bovine Tuberculosis. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28744263&form=6&db=m Recombinant Invasive Lactococcus lactis Carrying a DNA Vaccine Coding the Ag85A Antigen Increases INF-?, IL-6, and TNF-? Cytokines after Intranasal Immunization. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28775896&form=6&db=m Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. therapeutic application,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29386070&form=6&db=m Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29594592&form=6&db=m Selection of DNA aptamers against Mycobacterium tuberculosis Ag85A, and its application in a graphene oxide-based fluorometric assay. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29727142&form=6&db=m [Expression and immunogenicity of Ag85A protein of Mycobacterium tuberculosis]. diagnostic usage,ongoing research,unassigned 3,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30312318&form=6&db=m Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30687792&form=6&db=m Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30851131&form=6&db=m Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. causal interaction,ongoing research,unassigned 1,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30939065&form=6&db=m Transforming Growth Factor-? Suppresses Interleukin (IL)-2 and IL-1? Production in HIV-Tuberculosis Co-Infection. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31038197&form=6&db=m MVA85A vaccine to enhance BCG for preventing tuberculosis. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31039172&form=6&db=m Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. diagnostic usage,ongoing research,unassigned 2,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31384722&form=6&db=m EXPRESSION OF IMMUNOGLOBULIN, GRANZYME-B AND PERFORIN AGAINST Ag85A AND Ag85B PROTEINS OF MYCOBACTERIUM TUBERCULOSIS IN BALB/C MICE. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31567046&form=6&db=m EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31741730&form=6&db=m Biochemical and microbiological evaluation of N-aryl urea derivatives against mycobacteria and mycobacterial hydrolases. ongoing research,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31743110&form=6&db=m BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. diagnostic usage,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31786669&form=6&db=m Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31907319&form=6&db=m Host protein glycosylation in nucleic acid vaccines as a potential hurdle in vaccine design for nonviral pathogens. unassigned - 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31940294&form=6&db=m Diagnostic accuracy of combinations of serological biomarkers for identifying clinical tuberculosis. ongoing research,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31942003&form=6&db=m Intranasal vaccination with Listeria ivanovii as vector of Mycobacterium tuberculosis antigens promotes specific lung-localized cellular and humoral immune responses. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32200279&form=6&db=m Identification of potential Mycolyltransferase Ag85C inhibitors of Mycobacterium tuberculosis H37Rv via Virtual High Throughput Screening and Binding free energy studies. diagnostic usage,therapeutic application,unassigned 1,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32325740&form=6&db=m Plant-Produced N-glycosylated Ag85A Exhibits Enhanced Vaccine Efficacy Against Mycobacterium tuberculosis HN878 Through Balanced Multifunctional Th1 T Cell Immunity. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32920150&form=6&db=m Integrated transcriptomic and quantitative proteomic analysis identifies potential RNA sensors that respond to the Ag85A DNA vaccine. ongoing research,unassigned 3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33072631&form=6&db=m IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33153191&form=6&db=m Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. therapeutic application,unassigned 1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33155529&form=6&db=m Weak spots inhibition in the Mycobacterium tuberculosis antigen 85C target for antitubercular drug design through selective irreversible covalent inhibitor-SER124. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33323656&form=6&db=m Investigating role of Mycobacterium tuberculosis secretory antigens in altering activation of T cell signaling events in Jurkat T cells. causal interaction,ongoing research,unassigned 2,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33333421&form=6&db=m Identification of potent Antigen 85C inhibitors of Mycobacterium tuberculosis via in-house lichen library and binding free energy studies Part-II. causal interaction,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33632562&form=6&db=m Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34093498&form=6&db=m Lactococcus lactis FNBPA+ (pValac:e6ag85a) Induces Cellular and Humoral Immune Responses After Oral Immunization of Mice. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34306256&form=6&db=m ESAT-6 and Ag85A Synthetic Peptides as Candidates for an Immunodiagnostic Test in Children with a Clinical Suspicion of Tuberculosis. diagnostic usage,unassigned 2,0 2.3.1.122 Tuberculosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34478259&form=6&db=m Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species. therapeutic application,unassigned 4,0 2.3.1.122 Tuberculosis, Bovine http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22120192&form=6&db=m Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Tuberculosis, Bovine http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28713817&form=6&db=m Generation of Monoclonal Antibodies against Ag85A Antigen of Mycobacterium tuberculosis and Application in a Competitive ELISA for Serodiagnosis of Bovine Tuberculosis. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Tuberculosis, Lymph Node http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212340&form=6&db=m Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. diagnostic usage,ongoing research,unassigned 4,4,0 2.3.1.122 Tuberculosis, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20212340&form=6&db=m Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. diagnostic usage,ongoing research,unassigned 4,4,0 2.3.1.122 Tuberculosis, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31198944&form=6&db=m Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation. ongoing research,unassigned 3,0 2.3.1.122 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22884511&form=6&db=m Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer. ongoing research,therapeutic application,unassigned 4,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11120838&form=6&db=m Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11854254&form=6&db=m Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. ongoing research,therapeutic application,unassigned 1,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15196215&form=6&db=m Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-GuĆ©rin. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15502839&form=6&db=m Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. diagnostic usage,ongoing research,unassigned 1,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15687020&form=6&db=m TB vaccines for the World. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15687027&form=6&db=m Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16870530&form=6&db=m Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. ongoing research,unassigned 4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17519853&form=6&db=m [Strategies for the development of new tuberculosis vaccines] ongoing research,unassigned 2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17957238&form=6&db=m Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials. ongoing research,therapeutic application,unassigned 1,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18621704&form=6&db=m In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. ongoing research,therapeutic application,unassigned 4,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18682270&form=6&db=m Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18698342&form=6&db=m Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. ongoing research,unassigned 2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19064635&form=6&db=m Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19151191&form=6&db=m Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. ongoing research,therapeutic application,unassigned 1,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19356615&form=6&db=m A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19367339&form=6&db=m MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. ongoing research,therapeutic application,unassigned 3,3,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19487476&form=6&db=m Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. therapeutic application,unassigned 2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20017188&form=6&db=m Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. therapeutic application,unassigned 1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21603645&form=6&db=m Dual neonate vaccine platform against HIV-1 and M. tuberculosis. therapeutic application,unassigned 4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21887254&form=6&db=m Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22085170&form=6&db=m Do new TB vaccines have a place in the Expanded Program on Immunization? therapeutic application,unassigned 1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22789508&form=6&db=m Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23284637&form=6&db=m Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. therapeutic application,unassigned 2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23391465&form=6&db=m Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. therapeutic application,unassigned 2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23844129&form=6&db=m Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24828094&form=6&db=m Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25151225&form=6&db=m Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. diagnostic usage,therapeutic application,unassigned 2,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25466778&form=6&db=m Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25726088&form=6&db=m Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. ongoing research,therapeutic application,unassigned 2,4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26351306&form=6&db=m Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26478198&form=6&db=m Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. therapeutic application,unassigned 4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27960596&form=6&db=m Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28633702&form=6&db=m Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. ongoing research,therapeutic application,unassigned 2,1,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28775896&form=6&db=m Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. therapeutic application,unassigned 3,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30687792&form=6&db=m Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. ongoing research,therapeutic application,unassigned 3,2,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31038197&form=6&db=m MVA85A vaccine to enhance BCG for preventing tuberculosis. unassigned - 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33072631&form=6&db=m IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations. causal interaction,therapeutic application,unassigned 3,4,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33549390&form=6&db=m Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. therapeutic application,unassigned 3,0 2.3.1.122 Vaccinia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33632562&form=6&db=m Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,2,0 2.3.1.122 Vesicular Stomatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18388911&form=6&db=m Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. ongoing research,therapeutic application,unassigned 3,3,0